La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Adherium Gestion

Gestion contrôle des critères 1/4

We currently do not have sufficient information about the CEO.

Informations clés

Paul Mastoridis

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	less than a year
Propriété du PDG	n/a
Durée moyenne d'occupation des postes de direction	less than a year
Durée moyenne du mandat des membres du conseil d'administration	8.7yrs

Mises à jour récentes de la gestion

Recent updates

PDG

Paul Mastoridis

less than a year

Titularisation

Dr. Paul Mastoridis is Chief Executive Officer of Adherium Limited from February 2024. Paul Mastoridis has many years experience in the pharmaceutical industry, pioneering and leading digital solutions in...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Louis Panaccio	Executive Chairman of the Board	2.5yrs	AU$110.50k	1.01% A$ 115.0k
Daniel Kaplon	Chief Financial Officer	1.8yrs	AU$305.22k	pas de données
Paul Mastoridis	Chief Executive Officer	less than a year	pas de données	pas de données
Francis White	Chief Operating Officer	less than a year	pas de données	pas de données
Chris Leigh-Lancaster	VP of Product & Technology	less than a year	pas de données	pas de données
Cassandra Thomas	Vice President of People and Culture	less than a year	pas de données	pas de données
Michael Motion	Consultant	3.3yrs	AU$1.14m	pas de données
Zoe Park	Head of Software	less than a year	pas de données	pas de données
Nancy She	Head of Supply Chain and Procurement	less than a year	pas de données	pas de données
Michael Gormack	Head of Devices	less than a year	pas de données	pas de données
Emily Austin	Company Secretary	no data	pas de données	pas de données
John Wilson	Executive Medical Director	7.9yrs	AU$12.71k	pas de données

0.6yrs

Durée moyenne de l'emploi

Gestion expérimentée: ADR's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Louis Panaccio	Executive Chairman of the Board	2.5yrs	AU$110.50k	1.01% A$ 115.0k
Bruce McHarrie	Independent Non-Executive Director	9.1yrs	AU$55.25k	0.049% A$ 5.6k
William Hunter	Independent Non-Executive Director	8.7yrs	AU$50.00k	0.027% A$ 3.1k
Jeremy Curnock-Cook	Independent Non-Executive Director	9.3yrs	AU$50.00k	0.024% A$ 2.7k
George Baran	Non-Executive Director	3.3yrs	AU$50.00k	0.99% A$ 112.5k

8.7yrs

Durée moyenne de l'emploi

66yo

Âge moyen

Conseil d'administration expérimenté: ADR's board of directors are considered experienced (8.7 years average tenure).

Adherium Gestion

Gestion contrôle des critères 1/4

Informations clés

Mises à jour récentes de la gestion

Adherium Limited, Annual General Meeting, Nov 30, 2023

Adherium Limited Announces Resignation of Mark Licciardo as Joint Company Secretary

Adherium Limited Announces Executive Changes

Adherium Announces James Ward-Lilley Step Down from the Board

Adherium Limited, Annual General Meeting, Nov 29, 2022

Adherium Limited Appoints Daniel Kaplon as Chief Financial Officer, Effective 10 October 2022

Recent updates

Adherium Limited has filed a Follow-on Equity Offering in the amount of AUD 1.57 million.

New minor risk - Shareholder dilution

New major risk - Financial position

New major risk - Market cap size

New major risk - Market cap size

Adherium Limited, Annual General Meeting, Nov 30, 2023

Full year 2023 earnings released: AU$0.002 loss per share (vs AU$0.005 loss in FY 2022)

New major risk - Financial position

New minor risk - Financial data availability

New major risk - Revenue size

Adherium Limited Announces Resignation of Mark Licciardo as Joint Company Secretary

Adherium Limited Announces Executive Changes

Adherium Limited Commences Production and Market Release of the New, Next Generation Ellipta Sensor

Adherium Limited Receives Australian Therapeutic Goods Administration Approval for Next Generation Sensors

Adherium Announces James Ward-Lilley Step Down from the Board

Adherium Limited Receives U.S. FDA 510(k) Clearance for GSK pMDI Inhaler Users to Remotely Monitor Physiological Parameters

Adherium Limited, Annual General Meeting, Nov 29, 2022

Adherium Limited Appoints Daniel Kaplon as Chief Financial Officer, Effective 10 October 2022

Full year 2022 earnings released: AU$0.005 loss per share (vs AU$0.017 loss in FY 2021)

Adherium Limited Submits FDA 510(K) Application for Next Generation Hailie Sensor for Teva MDI Inhalers

Adherium Limited Submits US FDA Application for Hailie for GSK pMDI inhalers

Adherium Limited Receives U.S. Food and Drug Administration Clearance for Hailie for Ellipta

Adherium Limited Announces Conclusion of Robert Spurr's Assignment as Interim CFO

Adherium Limited Releases Next Gen Platform Integration Services

Adherium Limited Submits US FDA 510(k) Application for Ellipta Inhaler Users to Connect to Hailie Platform with Physiological Parameters

Adherium Limited Announces Board Changes

Adherium Limited Announces That Manufacturing Started for Hailie® for Symbicort® Sensors with Physiological Parameters

Adherium Submits US FDS 510(k) Application for Next Generation Hailie Sensor with Physiological Measures

Adherium Limited announced that it expects to receive AUD 3 million in funding from Trudell Medical Limited, Bioscience Managers Pty Ltd

Independent Non-Executive Director has left the company

Adherium Limited Auditor Raises 'Going Concern' Doubt

Full year earnings released - AU$0.036 loss per share

PDG

Titularisation

Équipe de direction

Durée moyenne de l'emploi

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen